||2 years -20¡ãC Powder, 2 weeks4¡ãC in DMSO,6 months-80¡ãC in DMSO
Note: Products for research use only, not for human use
Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38¡À0.06 nM. Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1[3.
The plasma half-life of Semaglutide is 46h in mini-pigs following i.v. administration and semaglutide has an MRT of 63.6h after s.c. dosing to mini-pigs. Semaglutide improves 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairments. In addition, Semaglutide rescues the decrease of tyrosine hydroxylase (TH) levels, alleviates the inflammation response, reduces lipid peroxidation, inhibits the apoptosis pathway, and also increases autophagy- related protein expression, to protect dopaminergic neurons in the substantia nigra and striatum. Moreover, the long-acting GLP-1 analogue semaglutide is superior to liraglutide in most parameters. Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight.